FDA Clears Tm Bioscience Cystic Fibrosis Gene Test Via De Novo
This article was originally published in The Gray Sheet
Executive Summary
FDA's de novo clearance of Tm Bioscience's Tag-It cystic fibrosis test kit paves the way for other CFTR gene mutation detection assays to be categorized as Class II
You may also be interested in...
Ambiguity On Diagnostic Regs Has Led To Tough Choices, Says CEO
In the current regulatory environment for genetic tests, a manufacturer's best business plan may dictate an opposite path to market than its concerns about patient safety, says Tm Bioscience CEO Greg Hines
Ambiguity On Diagnostic Regs Has Led To Tough Choices, Says CEO
In the current regulatory environment for genetic tests, a manufacturer's best business plan may dictate an opposite path to market than its concerns about patient safety, says Tm Bioscience CEO Greg Hines
Tm Bioscience Hopes To Snare Large Laboratories With Automated Tag-It Test
Genetic test developer Tm Bioscience is banking on the improved throughput of an automated version of its genetic Tag-It cystic fibrosis kit to attract interest from the largest U.S. commercial clinical laboratories